Differences in second trimester risk estimates for trisomy 21 between Maglumi X3/Preaccu and Immulite/Prisca systems

Üstündağ Yasemin; Huysal Kağan; Yeşil Meryem Rümeysa

doi:10.1515/tjb-2023-0203

Türk Biyokimya Dergisi (Dec 2024)

Differences in second trimester risk estimates for trisomy 21 between Maglumi X3/Preaccu and Immulite/Prisca systems

Üstündağ Yasemin,
Huysal Kağan,
Yeşil Meryem Rümeysa

Affiliations

Üstündağ Yasemin: Department of Biochemistry, University of Health Sciences Bursa Yuksek Ihtisas Research and Training Hospital, Bursa, Türkiye
Huysal Kağan: Department of Biochemistry, University of Health Sciences Bursa Yuksek Ihtisas Research and Training Hospital, Bursa, Türkiye
Yeşil Meryem Rümeysa: Department of Biochemistry, University of Health Sciences Bursa Yuksek Ihtisas Research and Training Hospital, Bursa, Türkiye

DOI: https://doi.org/10.1515/tjb-2023-0203
Journal volume & issue: Vol. 50, no. 1
pp. 46 – 51

Abstract

Read online

Maternal serum alpha-fetoprotein (AFP), human chorionic gonadotropin (HCG) or free β-HCG, and unconjugated estriol (uE3) concentrations are used to screen trisomy 21 in the second trimester. The performance of different analytical platforms has an impact on individual risk estimates. The aim of this study is to compare the multiple of median (MoM) values and risk estimates generated by Maglumi X3 analyzer/Preaccu software with the Immulite 2000 XPi device/Prisca software.

Published in Türk Biyokimya Dergisi

ISSN: 1303-829X (Online)
Publisher: De Gruyter
Country of publisher: Germany
LCC subjects: Science: Chemistry: Organic chemistry: Biochemistry
Website: https://www.degruyter.com/journal/key/tjb/html

About the journal

Abstract

Keywords